Giant Biogene Holding Co., Ltd. (HKG:2367)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 30.53B -56.5% |
| Revenue (ttm) | 6.14B -0.4% |
| Net Income | 2.13B -7.2% |
| EPS | 2.01 -12.1% |
| Shares Out | 1.06B |
| PE Ratio | 14.28 |
| Forward PE | 13.91 |
| Dividend | 1.39 (4.83%) |
| Ex-Dividend Date | Jun 1, 2026 |
| Volume | 6,060,704 |
| Average Volume | 5,163,735 |
| Open | 28.76 |
| Previous Close | 28.76 |
| Day's Range | 28.76 - 30.40 |
| 52-Week Range | 27.20 - 87.10 |
| Beta | 0.67 |
| RSI | 45.23 |
| Earnings Date | May 27, 2026 |
About Giant Biogene Holding
Giant Biogene Holding Co., Ltd., an investment holding company, designs, develops, manufactures, and sells skin treatment products with recombinant collagen in the People’s Republic of China. It also develops and manufactures rare ginsenosides technology-based functional food products; and offers medical devices. The company provides its functional skincare products, medical dressings, and functional food products primarily under the Comfy, Collgene, Ke Yu, and SKIGIN brands. Giant Biogene Holding Co., Ltd. was founded in 2000 and is headquarte... [Read more]
Financial Performance
In 2025, Giant Biogene Holding's revenue was 5.52 billion, a decrease of -0.37% compared to the previous year's 5.54 billion. Earnings were 1.91 billion, a decrease of -7.15%.
Financial numbers in CNY Financial StatementsNews
Giant Biogene Bruised In A 'Battle Of The Skincare Belles'
A squabble involving false advertising claims by a sinking Bloomage Biotech against highflying rival Giant Biogene has captivated China, with no end in sight Key Takeaways: Shares of Giant Biogene hav...